(Q34053781)

30 July 2017

1 reference

title

Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease (English)

1 reference

Mycobacterium avium avium

30 July 2017

0 references

1 reference

Kuper JI

1

1 reference

PubMed ID

11020135

30 July 2017

D'Aprile M

series ordinal

2

1 reference

30 July 2017

1 September 2000

1 reference

Clinical Pharmacokinetics

30 July 2017

1 reference

30 July 2017

39

1 reference

30 July 2017

3

1 reference

30 July 2017

203-214

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200039030-00003

30 July 2017

0 references

cites work

The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites

1 reference

12 December 2020

Rifabutin-associated uveitis

1 reference

12 December 2020

Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection

1 reference

12 December 2020

Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network

1 reference

12 December 2020

Anterior uveitis associated with rifabutin medication in AIDS patients

1 reference

12 December 2020

The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin

1 reference

12 December 2020

Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS.

1 reference

12 December 2020

The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin

1 reference

12 December 2020

Rifabutin Prophylaxis and Uveitis

1 reference

12 December 2020

1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA)

1 reference

12 December 2020

Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex

1 reference

12 December 2020

A phase I evaluation of concomitant rifabutin and didanosine in symptomatic HIV-infected patients

1 reference

12 December 2020

Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole

1 reference

12 December 2020

Effect of clarithromycin on the pharmacokinetics of 2',3'-dideoxyinosine in patients who are seropositive for human immunodeficiency virus

1 reference

12 December 2020

A multiple-dose pharmacokinetic interaction study between didanosine (Videx) and ciprofloxacin (Cipro) in male subjects seropositive for HIV but asymptomatic

1 reference

12 December 2020

Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers

1 reference

12 December 2020

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease

1 reference

12 December 2020

Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention

1 reference

12 December 2020

Antifungal agents. Part II. The azoles

1 reference

12 December 2020

Cations in the didanosine tablet reduce ciprofloxacin bioavailability.

1 reference

12 December 2020

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

12 December 2020

Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients

1 reference

12 December 2020

Pharmacokinetic interaction between ritonavir and clarithromycin

1 reference

12 December 2020

Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.

1 reference

12 December 2020

Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition

1 reference

12 December 2020

Fluconazole and enhanced effect of rifabutin prophylaxis

1 reference

12 December 2020

Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients.

1 reference

12 December 2020

Biotransformation of pravastatin sodium in humans

1 reference

12 December 2020

Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection.

1 reference

12 December 2020

Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers.

1 reference

12 December 2020

Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus

1 reference

12 December 2020

Uveitis associated with rifabutin and macrolide therapy for Mycobacterium avium intracellulare infection in AIDS patients

1 reference

12 December 2020

Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents

1 reference

12 December 2020

Uveitis associated with rifabutin prophylaxis and itraconazole therapy

1 reference

12 December 2020

Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin

1 reference

12 December 2020

Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients.

1 reference

12 December 2020

Update: clinically significant cytochrome P-450 drug interactions

1 reference

12 December 2020

HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications

1 reference

12 December 2020

Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Indinavir concentrations and St John's wort.

1 reference

12 December 2020

Drug interactions of HIV protease inhibitors

1 reference

12 December 2020

10.2165/00003088-200039030-00003

Identifiers

DOI

1 reference

PubMed ID

11020135

Dimensions Publication ID

30 July 2017

0 references

1 reference

PubMed ID

11020135